I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
July 17, 2017
With the NASDAQ up all of the five (5) sessions last week and the IBB closing flat after 4 up days …
I’m nervous especially with forethcoming Q2 financial results, spending and cash positions
Investors should not dismiss the deviations of many pricing moves - we are always ready for the expected sector decline when this market “peters-out” which many expect.
A critical indication ahead of “our” universe’s open!
Pre-open indication: seven (7) with 5 BUY and 2 SELLs
This is a limited-time preview of RegMed Investor's morning call. To get the pre-open briefing, plus daily access of the happenings and realities of “our” universe ……SUBSCRIBE!
Don’t ignore this …
June 1, 2017
Calling out the recent 10-Q page 17’s paragraph re a 24 page legal filing - this is what BSTG did NOT want investors to know or read!
May 31, 2017
CYTX jumps +$0.04 or +4.08% to $1.01 with 113.05 shares traded – it’s still ONLY an OPTION - something is better than ... nothing!
January 28, 2017
What difference does a $1.00 subscription a day, $100.00 a quarter abating the lack of a portfolio ... enema!
Subscribe: http://www.regmedinvestors.com/create-account
July 14, 2017
The IBB was flat at 0.00%, IWM was up +0.22% with the XLV +0.67% while the VIX was down -3.43% along with the XBI -0.10% …
Read more because … unless you know what happened this week; it is hard to formulate a perspective for the next!
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
Pre-open indication: six (6) - 5 hits and 1 misses
I answer one question, in which company should investors commit and keep their money.
June 27, 2017
On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019
June 26, 2017
BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10
June 20, 2017
SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 SGMO prices 10 M shares at $7.25
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
